Reaction mass of propylidynetrimethanol and 2-ethylpropane-1,3-diol and 5-ethyl-1,3-dioxane-5-methanol

Endpoint summary

Description of key information

In a sub-chronic (90-day) repeated dose toxicity study (OECD 408) with the test substance Polyol TD, mild effects were observed mainly in the high dose group (1000 mg/kg bw/day) and included slight leucocytosis, increased cholesterol and triglycerides and centrilobular hepatocytic hypertrophy. The effects were reversible after the recovery period and not considered to be adverse. Therefore, the NOAEL from this study was 1000 mg/kg bw/day.

Key value for chemical safety assessment

Toxic effect type:

dose-dependent

Repeated dose toxicity: via oral route - systemic effects

Link to relevant study records

Reference

Endpoint:

sub-chronic toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

2019-11-04 to 2020-06-26

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Qualifier:

according to guideline

Guideline:

OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)

Version / remarks:

adopted 25 june 2018

Deviations:

no

Qualifier:

according to guideline

Guideline:

EU Method B.26 (Sub-Chronic Oral Toxicity Test: Repeated Dose 90-Day Oral Toxicity Study in Rodents)

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Limit test:

no

Specific details on test material used for the study:

- Name of test material (as cited in study report): Polyol TD
- Chemical name: Reaction mass of 2-ethylpropane-1,3-diol and 5-ethyl-1,3-dioxane-5-methanol and propylidynetrimethanol
- Batch no.: 7350
- Expiry date: 18 June 2020
- Appearance: Clear, colourless liquid
- Storage conditions: Store in sealed container under dry gas (Nitrogen) blanket, at ambient temperature, in dry area protected from direct sunlight and the elements

Species:

rat

Strain:

Sprague-Dawley

Details on species / strain selection:

The animals were male and female Sprague-Dawley Crl:CD(SD) rats (60 males, 60 females). The animals were supplied by Charles River Italia S.p.A, Calco (Lecco), Italy.

Sex:

male/female

Details on test animals or test system and environmental conditions:

The rats were aged 27-29 days old on arrival, and weighed 75-99 g. They were allowed to acclimatise to the laboratory conditions for 18 days prior to dosing, during which time the health status of the animals was assessed by thorough observations. After arrival, on 24 of October 2019, the weight range for each sex was determined and the animals were temporarily identified within the cage by means of a coloured mark on the tail. Body weights were in the range of 76.4-84.4 g for males and 66.2-72.9 g for females. A health check was then performed by a veterinarian.

The animals were housed in a limited access rodent facility. Animal room controls were set to maintain temperature and relative humidity at 22°C±2°C and 55%±15%, respectively; actual conditions were monitored, recorded and the records retained. No relevant deviations from these ranges were recorded during the study. There were approximately 15 to 20 air changes per hour and the rooms were lit by artificial light for 12 hours each day. The animals were housed up to 5 of one sex to a cage, in clear polysulfone solid bottomed cages as indicated in the relevant SOP. Nesting material was provided inside suitable bedding bags and changed at least twice a week. Drinking water was supplied ad libitum to each cage via water bottles, except when overnight urine samples were collected in the last week of treatment from main phase groups. A commercially available laboratory rodent diet (4 RF 21, Mucedola S.r.l., Via G. Galilei,4, 20019, Settimo Milanese (MI), Italy), with certified dietary levels of phytoestrogen (genistein less than 350μg/gram of diet), was offered ad libitum throughout the study, except in cases when water was restricted as mentioned above. There was no information available to indicate that any non-nutrient substance likely to influence the effect of the test item was present in the drinking water or the diet. Records of analyses of water and diet are kept on file at the test facility. Dated and signed records of activities relating to the day to day running and maintenance of the study in the animal house were recorded.

On the day of allocation (5 days prior to the start of treatment) all animals were weighed. Animals at the extremes of the weight distribution were excluded to leave the required number of animals. The rats were allocated to the 4 groups by computerised stratified randomisation to give approximately equal initial group mean body weights. Individuals were uniquely identified within the study by sex, tattoo on the hind feet and ear notch and housed up to 3 of one sex per cage. The cages were identified by a label recording the study number, animal numbers and details of treatment. The arrangement of cages in batteries was such that cages from each treatment group were evenly distributed across the battery(Figure 1) to minimise possible environmental effects. No replacements occurred after the first dose was administered.

Procedures and facilities were compliant with the requirements of the Directive 2010/63/EU on the protection of animals used for scientific purposes. The national transposition of the Directive is defined in Decreto Legislativo 26/2014. The test facility is fully accredited by AAALAC. Aspects of the protocol concerning animal welfare have been approved by the animal-welfare body.

Route of administration:

oral: gavage

Details on route of administration:

The test item was dissolved in the vehicle and administered orally by gavage at a dose volume of 10 mL/kg body weight. Control animals received the vehicle alone at the same dose volume. The dose was administered to each animal on the basis of the most recently recorded body weight and the volume administrated was recorded for each animal.

Vehicle:

water

Remarks:

softened water (by reverse osmosis)

Details on oral exposure:

PREPARATION OF DOSING SOLUTIONS:
The required amount of POLYOL TD was dissolved in the vehicle. Preparations were made weekly (concentrations of 10, 30 and 100 mg/mL) according to stability data obtained from a previous study (Study No. A3648).

VEHICLE
The vehicle was softened water (by reverse osmosis).

Analytical verification of doses or concentrations:

yes

Details on analytical verification of doses or concentrations:

Analytical verification available via a previous non-GLP stability study (ERBC Study no. A3648).

Duration of treatment / exposure:

13 consecutive weeks, followed by a recovery period of 4 weeks for 5 males and 5 females from groups 1 and 4. Animals in the main phase were dosed up until the day before necropsy.

Frequency of treatment:

All animals were dosed once a day, 7 days a week.

Dose / conc.:

0 mg/kg bw/day (nominal)

Remarks:

Group 1; includes recovery 4 wk phase

Dose / conc.:

100 mg/kg bw/day (nominal)

Remarks:

Group 2

Dose / conc.:

300 mg/kg bw/day (nominal)

Remarks:

Group 3

Dose / conc.:

1 000 mg/kg bw/day (nominal)

Remarks:

Group 4; includes recovery 4 wk phase

No. of animals per sex per dose:

Each main group comprised 10 male and 10 female rats. Control and high dose groups (group 1 & 4) included 5 additional animals per sex for 4 weeks of recovery.

Control animals:

yes, concurrent vehicle

Details on study design:

- Dose selection rationale:
Dose levels were selected in consultation with the Sponsor, based on information from a previous study (non-GLP ERBC Study No. E0419). In this study, the test item was administered at the dose levels of 100, 300 and 1000 mg/kg bw/day, for two consecutive weeks and no treatment-related clinical signs nor differences in body weight, body weight gain and food consumption were recorded. At clinical pathology evaluations, non-adverse alterations in some clinical chemistry parameters (such as urea, potassium and sodium) were recorded in females of the high dose group; however, the correlation with the test item was doubtful since no other changes were noted. No changes were observed in treated males. The post mortem macroscopic observations showed no relevant changes that could be related to treatment. For these above reasons, the high dose level tested of 1000 mg/kg bw/day was considered suitable for a toxicity study of longer duration.
- Other:
The Sprague Dawley SD rat was the species and strain of choice because it is accepted by many regulatory authorities and there are ample experience and background data on this species and strain.

The oral route was selected as it is a possible route of exposure of the test item in man and in agreement with authority’s decision.

Positive control:

None

Observations and examinations performed and frequency:

CAGE SIDE OBSERVATIONS: Yes
- Time schedule: All clinical signs were recorded for individual animals. Once before commencement of treatment and once daily during the study, each animal was observed and any clinical signs recorded. Observations were performed at the same time interval each day, the interval was selected taking into consideration the presence of post-dose reactions. From Day 1 to Day 71 of the treatment period, observations were performed approximately 2 hours post dose. Starting from Day 72, since clinical signs were noticed, observations were performed at approximately 30 minutes from administration.

DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Once before commencement of treatment and at least once per week during the study from the start of treatment, each animal was given a detailed clinical examination. Each animal was observed in an open arena. The test included observation and record of changes in gait and posture, reactivity to handling, presence of clonic or tonic movements, stereotypies or bizarre behaviour and effects on the autonomic nervous system (e.g. lachrymation, piloerection, unusual respiratory pattern). Changes in fur, skin, eyes, mucous membranes, occurrences of secretions and excretions were also recorded.

BODY WEIGHT: Yes
- Time schedule for examinations: Each animal was weighed on the day of allocation to treatment group, on the day that treatment commenced, weekly thereafter and just prior to necropsy

FOOD CONSUMPTION AND COMPOUND INTAKE:
The weight of food consumed by each cage of rats was recorded once during the allocation (5 days of allocation) and at weekly intervals from the start of treatment. The group mean daily intake per rat was calculated.

OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Both eyes of all animals were examined prior to the commencement of treatment by means of an ophthalmoscope, and by a slit-lamp microscope, after the instillation of 0.5% Tropicamide (Visumidriatic®, Visufarma, Rome, Italy). The eyes of all animals from high dose and control groups were re-examined during Week 13 of treatment.
- Dose groups that were examined: all animals

HAEMATOLOGY: Yes
- Time schedule for collection of blood: Prior to necropsy
- Anaesthetic used for blood collection: Yes (identity): isoflurane
- Animals fasted: Yes
- How many animals: blood samples were collected from all animals in main phase and recovery groups
- Parameters checked in table 1 were examined.

CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood:Prior to necropsy
- Anaesthetic used for blood collection: Yes (identity): isoflurane
- Animals fasted: Yes
- How many animals:all animals in main phase and recovery groups
- Parameters checked in table 2 were examined.

URINALYSIS: Yes
- Time schedule for collection of urine: last week of treatment
- Metabolism cages used for collection of urine:Not specified
- Animals fasted: Yes
- Parameters checked in table 3 were examined.

NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: Once during Weeks 12 of treatment and once during Week 4 of recovery an evaluation of sensory reactivity to stimuli of different modalities (e.g. auditory, visual and proprioceptive stimuli) and an assessment of grip strength was also performed. The motor activity (MA) was measured once during Week 12 of treatment and once during Week 4 of recovery.
- Dose groups that were examined: all animals
- Battery of functions tested: sensory reactivity to stimuli of different modalities (e.g. auditory, visual and proprioceptive stimuli), grip strength, motor activity

IMMUNOLOGY: No

OTHER:
- Thyroid hormone determination (T3, T4 and TSH):
During the last week of treatment, approximately from 9:00 to 10:00, blood samples of approximately 0.5 mL for thyroid hormone determination (T3, T4, TSH) were collected from the sublingual vein, under light isoflurane anaesthesia and condition of food deprivation. Samples collected on Week 13 (on 6 and 7 February 2020), were transferred into tubes containing no anticoagulant and centrifuged at room temperature. The serum obtained was divided in two aliquots and stored at -80°C pending analysis. From the 16th to 20th of April 2020, the collected samples were assayed to determine the serum levels of Total triiodothyronine (total T3), Total thyroxine (total T4) and Thyroid Stimulating Hormone (TSH) by a multiplex assay, using Luminex Magpix system and the MILLIPLEX MAP Rat Thyroid Magnetic Bead Panel kit (Merk Millipore, cat. no. RTHYMAG-30K).

- Oestrous cycle:
At the end of the treatment and recovery periods, just prior to necropsy, vaginal smears were taken from all animals.

Sacrifice and pathology:

GROSS PATHOLOGY: Yes
Animals that had completed the scheduled test period were killed by exsanguination under isoflurane anaesthesia. All animals were subjected to necropsy, supervised by a pathologist. Requisite organs, according to OECD TG 408, were weighed and the required tissue samples preserved in fixative. Necessary organ weights to body weights were calculated. Samples of all the tissues observed were fixed and preserved in 10% neutral buffered formalin (except eyes, optic nerves, Harderian glands, testes and epididymides which were fixed in Modified Davidson’s fluid and preserved in 70% ethyl alcohol).

HISTOPATHOLOGY: Yes
Histopathological examinations as outlined by TG 408 were performed on all animals in the control and high dose groups killed at the end of the 13 weeks of treatment and all specimens showing abnormalities in all main phase groups. Liver analysis was performed on all groups as possible treatment-related changes were observed. One cauda from one epididymis of each animal completing the scheduled test period in the high dose and the control group was taken for sperm count and evaluation of motility and morphology.

Other examinations:

- Sperm analysis:
During the necropsy procedure, one cauda from one epididymis of each animal completing the scheduled test period in the high dose and the control group was taken for sperm count and evaluation of motility and morphology. The animals of the mid- and low dose groups were dosed until the evaluation of the control and high dose animals was performed.

Statistics:

Differences between each treated group and the control group were assessed by Dunnett’s test using a pooled error variance. The homogeneity of the data was verified by Bartlett’s test before Dunnett’s test. If the data were found to be inhomogeneous a Modified t test (Cochran and Cox) was applied. Statistical analysis of histopathological finding was carried out by means of a nonparametric Kolmogorov-Smirnov test.

Clinical signs:

effects observed, treatment-related

Description (incidence and severity):

Salivation was noticed starting from Week 11, in both genders treated at 1000 mg/kg bw/day. Almost all males (14 out of 15) and females (11 out of 15) showed salivation after 30 minutes from dosing. It also appeared in some males treated with 300 mg/kg bw/day, at the end of Week 11 and/or beginning of Week 12 of the treatment period. Salivation was no longer observed during the recovery period.
Other signs, such as abrasion and scab on the tail, hairloss and tooth/teeth missing, were recorded during the study in single animals, with no correlation with the dose and were considered as minor clinical signs not related to the test item. During the recovery periodother signs recorded, such as swelling and hairloss, were considered as incidental and not relevant since the animals affected did not show any sign of toxicity during the treatment period.

Mortality:

no mortality observed

Body weight and weight changes:

effects observed, non-treatment-related

Description (incidence and severity):

The only statistically significant increase found (+127%), that was not considered related to treatment, was the mean absolute body weight gain of males treated at 1000 mg/kg bw/day, on Day 22 of the recovery period.

Food consumption and compound intake (if feeding study):

effects observed, non-treatment-related

Description (incidence and severity):

No treatment-related changes were observed in food consumption in male and female animals, during the treatment and recovery periods.
During the dosing period, only a slight statistically significant increase in food consumption was observed on Day 85 (+8%), in males treated at 1000 mg/kg bw/day.
During the treatment-free period, on Days 15 and 22, increases in food consumption were recorded in males of the high dose group, respectively +55% and +12%, but these variations were considered as incidental, without any correlation with the administration of the test item

Food efficiency:

not examined

Water consumption and compound intake (if drinking water study):

not examined

Ophthalmological findings:

no effects observed

Haematological findings:

effects observed, treatment-related

Description (incidence and severity):

Dosing phase:
Slight leucocytosis was recorded in males dosed at 300 and 1000 mg/kg bw/day. Compared with controls, changes were 31% and 57%, respectively, and involved mostly lymphocytes.
Mean corpuscular volume was statistically significantly decreased in males dosed at 1000 mg/kg bw/day (3% below controls). Due to the minimal severity (values were within the range of historical data), this finding was considered to be not adverse.
The other statistically significant differences between control and treated animals (haemoglobin in males, reticulocytes and lymphocytes in females) were recorded in animals dosed with 100 mg/kg bw/day, therefore they were considered to be unrelated to treatment.

Recovery phase:
In males, leucocytes were comparable with controls, confirming complete reversibility. In females, leucocytes were higher than controls. However, this was mostly due to the low control data; leucocytes values of the treated females were comparable with those recorded at end of the the dosing phase.

Clinical biochemistry findings:

effects observed, treatment-related

Description (incidence and severity):

Many of the findings were mostly due to changes in one male dosed at 1000 mg/kg bw/day (animal no. A3649082): compared with mean control data, this animal showed increases of alanine aminotransferase (3.2 fold), aspartate aminotransferase (2.4 fold), total bilirubin (2fold), total cholesterol (2.1 fold, both HDL and LDL) and triglycerides (2.8 fold). Due to the minimal incidence, these findings cannot be conclusively attributed to treatment.
Cholesterol and triglycerides changes were also recorded in a number of males dosed at 1000 mg/kg bw/day.
The other statistically significant differences between control and treated animals (BUN/urea in both sexes, protein and albumin in males) were not dose-related, therefore they were considered to be incidental. All findings recorded at Week 13 showed a complete reversibility after 4 weeks of recovery. One treated male (no. A3649096) showed an increase of aspartate aminotransferase (2.4fold). Similar finding was not recorded at dosing phase (with the exception of animal no. A3649082), therefore this was considered to be incidental.

After 4 weeks of recovery, all findings recorded at Week 13 showed a complete reversibility. One treated male (no. A3649096) showed an increase of aspartate aminotransferase (2.4 fold). Similar finding was not recorded at dosing phase (with the exception of animal no. A3649082), therefore this was considered to be incidental.Alanine aminotransferase was still higher than controls in males (1.4 fold). However, the severity of this finding was insufficient to represent an hepatic disease, therefore thischange was considered to be not adverse.

Endocrine findings:

effects observed, non-treatment-related

Description (incidence and severity):

- Thyroid hormone determination:
Mean values of thyroid stimulating hormone were lower than mean control data in all male groups. Changes were 21% to 53% with no clear dose-relation. Since low value was also recorded in one control male (no. A3649012), no dose-relation or statistically significance were achieved and no concurrent changes of the other hormones were recorded, this finding was considered to be of no toxicological relevance.The statistically significant difference of thyroxine recorded between control and females dosed at 100 mg/kg bw/day (42% above controls) was not dose-related, therefore it was considered to be incidental.
At recovery phase, the differences recorded at dosing phase were no longer observed, confirming complete reversibility

- Oestrous cycle:
There were no treatment-related anomalies in the oestrous cycle of treated females at the end of the treatment and recovery periods.Normal physiology of the oestrous cycle (oestrous, metestrous, diestrous and proestrous) was noted in control and treated high dose females. No morphological changes were detected when compared to each “oestrous phase” in the ovaries, uterus/cervix and vagina. Furthermore, at necropsy, normal physiology of the oestrous cycle (oestrous, metestrous, diestrous and proestrous) was noted in control and treated high dose females. No morphological changes were detected when compared to each “oestrous phase” in the ovaries, uterus/cervix and vagina.

Urinalysis findings:

no effects observed

Behaviour (functional findings):

effects observed, non-treatment-related

Description (incidence and severity):

No relevant differences among groups were noted in landing foot splay, motor activity and sensory reactivity to stimuli results.
At the end of the treatment period, a slight but statistically significant increase in mean grip strength was recorded in females treated at 100 mg/kg bw/day (+16%). This increase was, however, not considered to be related to treatment since it was recorded only in females of the low dose group. At the end of recovery, this parameter was found increased in males (+31%), and decreased in females (-22%), treated at 1000 mg/kg bw/day. No toxicological significance was attributed to these findings, since these variations were not observed at the end of the treatment period but only at the end of the 4-week treatment free period. These finding were, thus, considered to be incidental and not treatment-related.

Immunological findings:

effects observed, non-treatment-related

Description (incidence and severity):

A statistically significant increase in absolute and relative mean spleen weights (approximately +17% of relative weight) was recorded in males treated at 1000 mg/kg bw/day, when compared to controls. However, since these weight variations were not accompanied by corroborating histopathological changes, these changes were considered not toxicologically relevant.
A slight leucocytosis in males treated at 300 and 1000 mg/kg bw/day, with a dose-relation trend, was recorded. Compared with controls, changes were 31% and 57%, respectively, and involved mostly lymphocytes.
The statistically significant decrease in lymphocytes in females dosed with 100 mg/kg bw/day was recorded without a dose-related trend, therefore this finding was considered to be unrelated to treatment.
Following the recovery period, in males, leucocytes were comparable with controls, confirming complete reversibility. In females, leucocytes were higher than controls. However, this was mostly due to the low control data; leucocytes values of the treated females were comparable with those recorded at end of the the dosing phase.

Organ weight findings including organ / body weight ratios:

effects observed, treatment-related

Description (incidence and severity):

A statistically significant mild increase in mean liver weight was recorded in males treated at 300 mg/kg bw/day (relative weight only) and 1000 mg/kg bw/day (absolute and relative weights), compared to controls. This increase was dose-related (+10% and+24% in mid- and high dose groups for relative weights) and accompanied by corroborative histopathological changes, such as centrilobular hypertrophy. A statistically significant increase in mean relative kidneys weight (approximately +11% of relative weight) and in absolute and relative mean spleen weights (approximately +17% of relative weight) was recorded in males treated at 1000 mg/kg bw/day, when compared to controls. However, since these weight variations were not accompanied by corroborating histopathological changes in both kidneys and spleen, these were considered not toxicologically relevant. The minimal statistically significant increase (+11%), still observed in the liver of males previously dosed at 1000 mg/kg bw/day, was considered not toxicologically relevant since, at histomorphology, the liver was comparable to control animals.

Gross pathological findings:

effects observed, non-treatment-related

Description (incidence and severity):

All observed changes were considered spontaneous and incidental, having a comparable incidence in control and treated groups and/or are characteristically seen in untreated Sprague Dawley SD rats of the same age. In particular, the mass observed at necropsy in the prostate of one high dose treated male (no. A3649082) corresponded microscopically to a benign prostatic adenoma in the ventral lobe and it was considered as a spontaneous pathology.

Neuropathological findings:

no effects observed

Histopathological findings: non-neoplastic:

effects observed, treatment-related

Description (incidence and severity):

Histopathological examination revealed treatment-related changes in the liver, which consisted in centrilobular hepatocytic hypertrophy, morphologically represented by an enlarged size of the hepatocytes, of males treated at 1000 mg/kg bw/day. This change was no longer observed at the end of the 4-week recovery period. This change correlated with the increased liver weight observed in mid- and high dose males and was most likely considered related to microsomal enzyme induction.
All other reported findings, including the benign prostatic adenoma in the prostate ventrallobe of a single high dose male (no. A3649082), were considered spontaneous and incidental, having a comparable incidence in control and treated groups. In particular, the nephropathy observed was not considered treatment-related because it was observed in male rats of all groups, including control animals; the nephropathy was characterised by tubular degeneration/regeneration and/or necrosis and/or granular casts, in some cases associated with mononuclear cell infiltration, localised in the cortex and/or in the cortical/medullary junction.

Histopathological findings: neoplastic:

not specified

Other effects:

effects observed, non-treatment-related

Description (incidence and severity):

- Sperm analysis:
No differences were seen in motility, morphology and concentration expressed as million sperm/gram caudal epididymal tissue. Since no treatment-related effects were seen between control and high dose males no assessment was performed in males of the mid- and low dose groups as well as on recovery groups. Furthermore, at necropsy, seminiferous tubules were evaluated with respect to their stage in the spermatogenic cycle and to the integrity of the various cell types within the different stages; the qualitative testis staging did not indicate any abnormalities in the integrity of the various cell types present within the different stages of the spermatogenic cycle (Stages I- XIV) in all control and treated males of the high dose group.

- Coagulation:
The statistically significant differences of activated partial thromboplastin time recorded between control and females dosed at 300 mg/kg bw/day was not dose related, therefore it was considered to be incidental. At recovery phase no changes were recorded.

Details on results:

For further details and tabular overviews of results, please refer to the attached full study report.

Dose descriptor:

NOAEL

Effect level:

1 000 mg/kg bw/day (nominal)

Based on:

test mat.

Sex:

male/female

Basis for effect level:

clinical biochemistry

other: The effects seen in males, slight leucocytosis, increased cholesterol and triglycerides levels and centrilobular hepatocytocytic hypertrophy in the liver, were treatment related, but reversible and therefore the not defined as adverse effects.

Dose descriptor:

NOEL

Effect level:

100 mg/kg bw/day (nominal)

Based on:

test mat.

Sex:

male

Basis for effect level:

other: The slight leucocytosis and increased cholesterol and triglycerides and the histopathological effects (centrilobular hepatocytic hypertrophy) in males were considered to be related to treatment but, reversible and therefore not defined as adverse effects.

Key result

Critical effects observed:

no

Conclusions:

A repeated dose 90-day oral toxicity study with exposure to Polyol TD by daily gavage in the rat was performed according to OECD guideline and GLP principles. No Observed Adverse Effect Level (NOAEL) for this study was 1000 mg/kg bw/day and the No Observed Effect Level (NOEL) was 100 mg/kg bw/day. There was slight leucocytosis in males treated at 300 and 1000 mg/kg bw/day, increased cholesterol and triglycerides in some males dosed at 1000 mg/kg bw/day and centrilobular hepatocytic hypertrophy in the liver of males dosed at 1000 mg/kg bw/day. The above findings were treatment related, but were no longer observed at the end of the recovery period and therefore were not defined as adverse effects.

Executive summary:

In a GLP-compliant subchronic toxicity study performed according to OECD Guideline 408, Polyol TD (in water) was administered to 10 Sprague Dawley rats/sex/dose once daily, 7 days per week for 13 consecutive weeks by oral gavage at dose levels of 100, 300 and 1000 mg/kg bw/day. In addition, 5 rats/sex from the control and high dose group (1000 mg/kg bw/day) were included in a treatment-free recovery group for a period of 4 weeks post-dosing.

The following investigations were performed: daily clinical signs, weekly detailed clinical signs (removal from cage and open field observations), evaluation of sensory reactivity to stimuli and motor activity, body weight, food consumption, ophthalmoscopy, oestrous cycle, clinical pathology investigations, sperm analysis, terminal body weight, organ weights, macroscopic observations and histopathological examinations.

 

Signs of effects related to treatment were mainly observed in animals from the high dose group. Most of these effects were recorded at clinical pathology evaluations (slight leucocytosis in males treated at 300 and 1000 mg/kg bw/day, with a dose-related trend and increased cholesterol and triglycerides in some males dosed at 1000 mg/kg bw/day) and at histopathology (centrilobular hepatocytic hypertrophy in the liver of males dosed at 1000 mg/kg bw/day). These findings were considered to be related to treatment but, since they were no longer observed at the end of the recovery period, they were not defined as adverse effects.

 

Based on the above mentioned results, it can be concluded that the No Observed Adverse Effect Level (NOAEL) for this study was 1000 mg/kg bw/day and the No Observed Effect Level(NOEL) was 100 mg/kg bw/day.

 

This subchronic toxicity study in the rat is acceptable and satisfies the guideline requirement for a subschronic oral study (OECD TG 408; EU Method B.26) in rats.

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

NOAEL

1 000 mg/kg bw/day

Study duration:

subchronic

Species:

rat

Quality of whole database:

The NOAEL is derived from a GLP-compliant subchronic toxicity study which was performed according to OECD TG 408.

Repeated dose toxicity: inhalation - systemic effects

Endpoint conclusion

Endpoint conclusion:

no study available

Repeated dose toxicity: inhalation - local effects

Endpoint conclusion

Endpoint conclusion:

no study available

Repeated dose toxicity: dermal - systemic effects

Endpoint conclusion

Endpoint conclusion:

no study available

Repeated dose toxicity: dermal - local effects

Endpoint conclusion

Endpoint conclusion:

no study available

Additional information

In a GLP-compliant 90-day repeated dose toxicity study performed according to OECD TG 408, the test substance Polyol TD (Reaction mass of 2-ethylpropane-1,3-diol and 5-ethyl-1,3-dioxane-5-methanol and propylidynetrimethanol; EC 904-153-2) did not reveal significant systemic toxicity after administration to 10 Sprague Dawley rats/sex/dose once daily, 7 days per week for 13 consecutive weeks by oral gavage at dose levels of 100, 300 and 1000 mg/kg bw/day.

An additional recovery group, consisting of 5 rats/sex from the control and high dose group (1000 mg/kg bw/day) were included to evaluate the reversibility of effects after a treatment-free period of 4 weeks post-dosing.

Investigations included daily clinical signs, weekly detailed clinical signs (removal from cage and open field observations), evaluation of sensory reactivity to stimuli and motor activity, body weight, food consumption, ophthalmoscopy, oestrous cycle, clinical pathology investigations, sperm analysis, terminal body weight, organ weights, macroscopic observations and histopathological examinations.

Effects were mainly observed at the highest dose tested (1000 mg/kg bw/day) and included slight leucocytosis in males treated at 300 and 1000 mg/kg bw/day, with a dose-related trend and increased cholesterol and triglycerides in some males dosed at 1000 mg/kg bw/day. Histopathology revealed centrilobular hepatocytic hypertrophy in the liver of males dosed at 1000 mg/kg bw/day. These findings were considered to be related to treatment but, since they were no longer observed at the end of the recovery period, they were not defined as adverse effects.

This study therefore reported a NOAEL of 1000 mg/kg bw/day (i.e. the highest dose tested) and a NOEL of 100 mg/kg bw/day.

Justification for classification or non-classification

Based on the information provided from an OECD TG 408-compliant subchronic repeated dose toxicity study, Polyol TD does not warrant classification for repeated dose toxicity according to Regulation (EC) No. 1272/2008.